Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 6/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | CCND1 | P24385 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694678 | 0.92 | MAPK8 (0.31) | MAPK8CDK1CDK4CCND1CDK2 | |
| SCHEMBL694684 | 0.92 | MAPK8 (0.31) | MAPK8CDK1CDK4CCND1CDK2 | |
| SCHEMBL695508 | 0.91 | ALK (0.32) | MAPK8CDK1CDK4CCND1CDK2 | |
| SCHEMBL694998 | 0.88 | OPRM1 (0.34) | MAPK8ENPP1MAPK14DGAT1CDK2 | |
| SCHEMBL694943 | 0.87 | MAPK14 (0.36) | MAPK8MAPK14DGAT1TDO2 | |
| SCHEMBL694576 | 0.86 | CDK2 (0.33) | MAPK8MAPK14TDO2CDK1CDK4 | |
| SCHEMBL695950 | 0.86 | CDK2 (0.33) | MAPK8MAPK14TDO2CDK1CDK4 | |
| SCHEMBL2680399 | 0.85 | DNMT3A (0.40) | — | |
| SCHEMBL694055 | 0.85 | CDK2 (0.35) | MAPK14TDO2CDK1CDK4CCND1 | |
| SCHEMBL695339 | 0.85 | CDK2 (0.33) | MAPK8MAPK14TDO2CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421864-B1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-08-06 | — | — | EP | disclosed |
| US-8461175-B2 | 1-pyrazolo[4,3-c]isoquinoline derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2421864-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122272-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115898-A1 | 1-PYRAZOLO[4,3-C]ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, CYP4F3, HCCS | MAPK8 4023/4885ENPP1 4718/4885MAPK14 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.